Keywords:
molecular pathology; uterine sarcoma; leiomyosarcoma; endometrial stromal sarcoma; TP53; RB1; gene fusions; NGS.References
1. Alodaini A.A., Alabdulqader N., Alabdulqader A. et al. Uterine Mesenchymal Tumors: Updates on Pathology, Molecular Landscape, and Therapeutics. Medicina. 2024;60(7):1085. doi:10. 3390/medicina60071085.
2. Chiang S. Molecular Pathogenesis of Uterine Sarcomas: Mechanisms and Implications for Treatment. Annu Rev Pathol. 2026;21(1):239–267. doi:10.1146/annurev-pathmechdis-111523-02 3434.
3. Croce S. et al. Diagnosis of uterine sarcomas and rare uterine mesenchymal tumors with malignant potential: French Sarcoma Group and Rare Gynecological Tumours guidelines. Gynecol Oncol. 2023. PMID:37806863.
4. Kim K., Kim S., Ahn T. et al. A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis. BMC Cancer. 2023;23:1215. doi:10.1186/s12885-023-11394-0.
5. Pérez-Fidalgo J.A. et al. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by the Spanish Group for Research on Sarcomas (GEIS). Ther Adv Med Oncol. 2023;15:17588359231157645. doi:10.1177/17588359231157645.
6. Ray-Coquard I., Casali P.G., Croce S. et al. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas. Int J Gynecol Cancer. 2024;34(10):1499–1521. doi:10.1136/ijgc-2024-005823.
7. Wang W. et al. Advancement in multi-omics approaches for uterine sarcoma. Cell Biosci. 2024;14. doi:10.1186/s40364-024-00673-y.
8. WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed. Lyon: IARC; 2020.
